From Targets to Treatments: Bridging Autoimmune Research to Advance Understanding of Alopecia Areata

Alopecia Areata Research Summit
Thursday, December 4 & Friday, December 5, 2014
Hyatt Regency Bethesda, Maryland

Program

THURSDAY, DECEMBER 4TH
Breakfast
7:30 AM – 8:00 AM

Session 1 – Introduction & Overview
8:00 AM – 8:50 AM
8:00 AM – 8:05 AM
Dory Kranz, NAAF; David A. Norris, MD; Julian Mackay-Wiggan, MD, MS; Jeffrey Frelinger, PhD
Introduction

8:05 AM – 8:15 AM
Steve Katz or Bob Carter, NIAMS
Welcome

8:15 AM – 8:35 AM
David A. Norris, MD
Overview of alopecia areata and progress from preceding summits: what we have learned and where we are headed

8:35 AM – 8:50 AM
Discussion (led by Dr. Norris)

Session 2 – Functional Genetics, Genomic Research & Rationally Selected Targets for Treatment
8:50 AM – 10:35 AM
Moderator: TBD

8:50 AM – 9:05 AM
Angela M. Christiano, PhD, Columbia University
Alopecia areata GWAS studies: discoveries, connections and implications

8:50 AM – 9:05 AM
Ricardo Cibotti, PhD, NIAMS
NIAMS funding opportunities: the critical role of a Registry in genomic research
Surprise award to Madeleine Duvic for Alopecia Areata Registry, Biobank and Clinical Trials Network

9:10 AM – 9:25 AM
Julian Mackay-Wiggan, MD, PhD, Columbia University
Clinical trials exploring the efficacy of rationally selected therapies in alopecia areata

9:30 AM – 9:40 AM
Speaker suggested by AARDA
Common drugs to treat autoimmune diseases

9:45 AM – 9:55 AM
Ricardo R. Cibotti, PhD, NIAMS
NIAMS funding opportunities: the critical role of a Registry in genomic research
10:00 AM – 10:10 AM  
Linda Wicker, PhD, CU Cambridge Institute for Medical Research  
*Discovering genes that influence the development of type 1 diabetes and other autoimmune diseases*

10:15 AM – 10:25 AM  
LTC Jon Meyerle, MD, Uniformed Services University of the Health Sciences  
*The DOD Serum Repository: experience with melanoma and developing an approach for alopecia areata*

10:25 AM – 10:50 AM  
Discussion

Break (All Posters Open for Viewing)  
10:50 AM – 11:00 AM

Session 3 – Developing a Clinical Research Platform: Biomarkers, Early Detection & Prevention  
11:00 AM –

11:00 AM – 11:10 AM  
Ali Jabbari, MD, PhD, Columbia University  
*Update on alopecia areata biomarker studies*

11:15 AM – 11:25 AM  
Thomas A. Waldmann, MD, NIH, NCI Cytokine Immunology  
Or Raphael Clynes, MD, PhD, Columbia University  
*Measurement of IL-15R alpha/IL-15 in patients with alopecia areata*

11:30 AM – 11:40 AM  
Dennis Roop, PhD, University of Colorado  
*Using alopecia areata patients’ sera to identify antigens that are targets of alopecia areata patients’ autoantibodies*

11:45 AM – 11:55 AM  
Ralf Paus, MD, University of Luebeck  
*Clonotype analysis of alopecia areata-specific CD8 T-lymphocytes*

12:00 PM – 12:10 PM  
Gerald T. Nepom, MD, PhD, UW/Benaroya Research Institute/Immune Tolerance Network  
*Molecular genetic mechanisms triggering autoimmune diseases and predicting response to therapy*

12:15 PM – 12:25 PM  
Judith A. James, MD, PhD, University of Oklahoma  
*Diagnostic and preventive research in other autoimmune diseases and development of detection algorithms for alopecia areata*

12:25 PM – 12:50 PM  
Discussion

Lunch, Presentation, Networking & Discussion  
12:50 PM – 1:30 PM

Director of the National Institutes of Health: Francis S. Collins, MD, PhD  
*The Accelerating Medicines Partnership*  
1st Backup: Anthony S. Fauci, MD, Director of NIAID  
2nd Backup: Stephen I. Katz, MD, PhD, Director of NIAMS
Session 4 – Immunology & Autoimmunity: Implications for Future Alopecia Areata Research
1:30 PM – 3:20 PM
Moderator: TBD

1:30 PM – 1:40 PM
Noel Rose, MD, PhD, Johns Hopkins
The importance of epitope mapping and epitope mimicry in autoimmune disease understanding and treatment development

1:45 PM – 1:55 PM
Yehuda Shoenfeld, MD, PhD, Sheba Medical Center for Autoimmune Diseases
Epitopes, autoimmunity, and infectious triggers

2:00 PM – 2:10 PM
Timothy G. Behrens, MD, Genentech
Bringing immunology to clinical relevance

2:15 PM – 2:25 PM
Luis A. Diaz, MD, University of North Carolina
Skin immunity and immunology

2:30 PM – 2:40 PM
Kurt Griffin, MD, PhD, Sanford Research/University of South Dakota
Immunology of type 1 Diabetes

2:45 PM – 2:55 PM
Daniel Rotrosen, MD, Director of NIAID Division of Allergy, Immunology, and Transplantation (DAIT)
Update on DAIT support, the Human Immune Phenotyping Centers and other resources

2:55 PM – 3:20 PM
Discussion

Break (All Posters Open for Viewing)
3:20 PM – 3:30 PM

Session 5 – Evaluation of Animal Model Technologies and Implications for the Future
3:30 PM – 4:50 PM
Moderator: John P. Sundberg, DVM, PhD

3:30 PM – 3:40 PM
Yosef Rafaeli, PhD, University of Colorado
Or Amos Gilhar, MD, Technion Israel Institute of Technology
Engineered mouse models: advantages and challenges of existing grafting model

3:45 PM – 3:55 PM
Lishan Su, PhD, University of North Carolina
Humanized mouse model to study immunopathogenesis and implications for alopecia areata

4:00 PM – 4:10 PM
Richard A. Flavell, PhD, RFS, Yale
Use of transgenic and gene-targeted mice to study innate and adaptive immunity
4:15 PM – 4:25 PM
Jonathan W. Yewdell, MD, PhD, NIAID
Understanding the interaction between the immune system and viruses using mouse infection models

Backup: Thomas A. Wynn, PhD NIAID
Transgenic and knockout mouse models to dissect the mechanisms of fibrosis

4:25 PM – 4:50 PM
Discussion

Break (All Posters Open for Viewing)
4:50 PM – 5:00 PM

Session 6 – New Directions: Microbiome
5:00 PM – 6:00 PM
Moderator: TBD

5:00 PM – 5:10 PM
Yasmine Belkaid, PhD, NIAID
Relationship of the skin and gut in the development and management of autoimmune and inflammatory diseases

5:15 PM – 5:25 PM
David Artis, PhD, University of Pennsylvania
Pathways that regulate innate and adaptive immune cell function

5:30 PM – 5:40 PM
Lita M. Proctor, PhD, NHGRI
The Human Microbiome Project

5:40 PM – 6:00 PM
Discussion

Cocktails, Networking & Poster Presentations
6:00 PM – 6:45 PM
At this time, Drs. (names) will be present to answer questions at their poster displays which are available for viewing throughout the meeting.

Dinner & Presentation
7:00 PM – 7:50 PM
Maria Beckett
The need for a treatment: a patient’s perspective

FRIDAY, DECEMBER 5TH

Breakfast
7:30 AM – 8:00 AM

Session 7 – Understanding the Importance of Burden of Disease Studies and Assessing the Need for Alopecia Areata
8:00 AM – 9:25 AM
Moderator: TBD

8:00 AM – 8:10 AM
Rick Kittles, PhD, University of Illinois
Studying race and genetic health disparities in autoimmune diseases

8:15 AM – 8:30 AM
Mary-Margaret Chren, MD, UCSF
What we know about alopecia areata epidemiology, burden of disease and natural history
Siobhán O'Connor, MD, MPH, CDC
Infectious etiologies of chronic diseases: integrating laboratory science, epidemiology and surveillance to define causal links between recognized and novel infectious agents and chronic syndromes

Antonella Tosti, MD, University of Miami
Alopecia areata and comorbid conditions

Break (All Posters Open for Viewing)

Session 8 - Engaging Biopharma in alopecia areata research
9:40 AM – 11:50 AM
Moderator: TBD

9:40 AM – 9:50 AM
James A. Solomon, MD, PhD, Ameriderm
Uniform Alopecia Areata Clinical Trials Protocol

9:55 AM – 10:05 AM
June Zhao, AstraZeneca
Working alopecia areata into product life cycle management

10:10 AM – 10:20 AM
Christopher P. Austin, MD, NCATS
Lessons from NCATS about bridging academia and biopharmaceutical industry in service of research

10:25 AM – 10:35 AM
Katherine Needleman, MS, PhD, RAC, FDA Orphan Grants Program
Making the case that universalis and totalis are medically distinct from alopecia areata patchy and qualify for Orphan Drug Status

10:40 AM – 10:50 AM
Maren T. Scheuner, MD, MPH, VA Health Services
Engaging the nation’s largest healthcare system (the VA) in alopecia areata clinical research

10:55 AM – 11:05 AM
Janet Woodcock, MD, FDA CDER
Clinical endpoints for disease, the FDA experience. PFDDI, process for autoimmune treatment review and potential to move alopecia areata from dermatology

Break (All Posters Open for Viewing)
11:35 AM – 11:50 AM
11:50 AM – 12:50 PM
Lunch & Session 9: Group Breakouts
(Co-chairs meet to develop summary and future directions)

1. Immunology & autoimmunity
   Group Leader: Yewdell (Belkaid as backup)
2. Genetics & clinical research
   Group Leader: Gary Nepom (Rick Kittles or Luis Diaz as backup)
3. Animal models
   Group Leader: Lishan Su or Richard Flavell
4. Microbiome
   Group Leader: TBD
5. Epidemiology, natural history & burden of disease
   Group Leader: TBD

12:50 PM – 1:30 PM
Breakout Reports

1. Immunology & autoimmunity
   Group Leader: TBD
2. Genetics & clinical research
   Group Leader: TBD
3. Animal models
   Group Leader: TBD
4. Microbiome
   Group Leader: TBD
5. Epidemiology, natural history & burden of disease
   Group Leader: TBD

Break (All Posters Open for Viewing)
1:30 PM – 1:40 PM

Session 10 - Summary & Future Directions
1:40 PM – 2:45 PM

1:40 PM – 1:55 PM
David A. Norris, MD
Meeting summary, outcomes and charting a course for future research

2:00 PM – 2:15 PM
Jeffrey Frelinger, PhD
Immunology and autoimmunity assignments and action plan

2:20 PM – 2:35 PM
Julian Mackay-Wiggan, MD, MS
Clinical assignments and action plan

2:35 PM – 2:45 PM
Discussion

Keynote Address & Meeting Close
2:45 PM – 3:15 PM
Rear Admiral Boris D. Lushniak, MD, MPH
Acting United States Surgeon General